ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 2, 2012
Chipotle Misses on Bottom Line in Fourth Quarter; Shares Remain Significantly Overvalued
Chipotle posted fourth-quarter earnings that missed consensus estimates. Though management raised its conservative same-store-sales growth forecast for 2012, we think the shares are significantly overvalued. We are strongly considering re-establishing a put option on the company in the portfolio of our Best Ideas Newsletter.
Feb 2, 2012
Broadcom Pops 8% Today; The Firm's Shares Still Remain Undervalued
Last week, we highlighted Broadcom as undervalued. The shares popped 8% today on strong quarterly results and a better-than-expected outlook, and we think there is further upside to come based on valuation.
Feb 2, 2012
Mattel Ups Dividend 35%, to $1.24 per Share; Boasts 4% Annual Yield and Solid Valuentum Dividend Cushion Score
Though we hold peer Hasbro in the portfolio of our Dividend Growth Newsletter, we're not against considering Mattel, which recently raised its dividend 35% and now boasts an annual yield of 4%. Our dividend report flagged the potential growth in the company's dividend as excellent.
Feb 2, 2012
Exxon Issues Fourth-Quarter Results; Yield Still Comparatively Weak
Exxon posted earnings growth of a meager 2% in its fourth quarter, and its annual dividend yield remains below that of more attractive energy peers.
Feb 1, 2012
Valuentum's February Edition of its Dividend Growth Newsletter!
The February edition of our Dividend Growth Newsletter is now available.
Feb 1, 2012
UPS Posts Solid Adjusted Fourth-Quarter Results; Sees Strong Package Delivery Growth in US
Economic bellwether UPS reported fourth-quarter results that reinforce our view that the US will avoid a double-dip recession despite the well-documented slowdown in Europe.
Feb 1, 2012
Pfizer, Eli Lilly Post Fourth-Quarter Results; Both Score High on Our Valuentum Dividend Cushion
Pfizer and Eli Lilly posted fourth-quarter results with each showing the impact of the industry's "patent cliff." Pfizer has lost exclusivity of Lipitor, while Eli Lilly is now facing competition for its blockbuster drug Zyprexa. Though their respective outlooks remain challenged, the safety of their current dividends remains excellent based on their respective Valuentum Dividend Cushion scores.
Jan 29, 2012
Honeywell Expects Strong 2012 Despite Downturn in Europe During First Half
Honeywell posted strong fourth-quarter results and noted that organic sales and earnings will expand in 2012 despite challenges in Europe. The industrial conglomerate continues to see strength across all four of its business segments.
Jan 27, 2012
Synaptics Experiencing Relative Strength Today
Synaptics reported better-than-expected fiscal second-quarter earnings yesterday, and the stock is seeing nice relative strength today. We think this interesting firm, known for its Touchpad interface, has further valuation upside.
Jan 27, 2012
P&G Reduces 2012 Outlook; Expects Dividend Increase This Year
Proctor & Gamble issued decent fiscal second-quarter results but its outlook for 2012 was plagued by head winds from currency, taxes, and commodity costs. Still, we think P&G is a core holding in our Dividend Growth portfolio.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.